For research on Antibody-based immunotherapies at Department of Physics, TUM.
Antibody-based immunotherapies have great potential for the treatment of tumor diseases. However, an over-stimulation of the immune system can lead to side effects that require the therapy to be discontinued. This overstimulation has two causes: First, the target antigens are often present both on the tumor tissue and on the healthy tissue. Secondly, the antibodies are active throughout the body and not only locally on the tumor. In order to solve these problems, our team aims to develop an „on/off button“ for antibody immunotherapies. This is an ultraminiaturized nanoswitch made of DNA. The nanoswitch can specifically recognize tumor cells and recruit the body’s own immune cells to fight these cells. This enables the immune system to fight tumor cells in a targeted and „on demand“ manner and leads to lower activity on healthy tissue and thus to fewer side effects. Our long-term goal is to use the DNA platform in cooperation with pharmaceutical companies to develop therapeutics against various tumor diseases. To turn this project into realty our team consisting of 7 people including 3 Post-Docs and 4 bachelor and
master students with a strong background in biophysics and biochemistry is looking for further expertise in various fields of research, including molecular biology, chemistry, immunology, and tumor biology. The team was already awarded with two prestigious pre-seed awards, the M4
award and the Medical-Valley Award, both in 2019.